Author:
Direct-to-patient (DTP) distribution has moved from experimental to expected. By most industry accounts, specialty pharma manufacturers now have a DTP program live, in pilot, or planned for next year. But a strange pattern has emerged across the industry. Launching a DTP channel and succeeding with one are often treated as the same milestone, though the two are usually quite different.
A program can meet its go-live target date, onboard its first wave of patients, and still fail the people it was built for. That includes both the individuals relying on it to start and stay on treatment, and the commercial teams counting on it to move the needle. The industry doesn’t have a shortage of DTP launches. It has a shortage of agreed-upon definitions for what a good one actually looks like across the full prescription journey.
The Manufacturer Side of “Good”
For commercial and market access teams, a successful DTP program isn’t just operational uptime. It’s a complete data picture across a part of the prescription journey that used to be a black box.
Knowing where a patient stands in the journey today is worth more than a monthly report showing where they stood three weeks ago. Manufacturers who can see bottlenecks as they form, rather than discovering them during a quarterly review, have a real chance to intervene before a patient drops off entirely.
Speed matters too, but often the wrong speed gets measured. Plenty of programs track speed to launch without tracking speed to therapy, the time from prescription to first dose, even though that second number is the one that actually reflects whether the infrastructure is working.
There’s also a quieter factor that doesn’t get talked about enough. Every additional vendor or system a prescription touches creates another point where data can go stale or a patient can get lost. Consolidation isn’t really about reducing vendor count for its own sake. It’s about reducing the number of vulnerabilities where something can quietly fail without anyone noticing until it’s too late, a risk that grows with every handoff from intake to delivery.
The Patient Side of “Good”
None of this matters if it doesn’t translate into a better experience for the person actually living the prescription journey. From the patient’s side, “good” tends to look less like technology and more like certainty.
Patients will tolerate a longer timeline far more readily than they will tolerate ambiguity about its status or its end date. A proactive status update, even a simple one, reduces abandonment more effectively than shaving a day off fulfillment time ever could.
Getting a patient their first fill is the easy part of the job. The harder question, and the more important one, is whether the infrastructure actually helps them start and stay on treatment at month three, month six, and month twelve. For chronic or complex conditions, the first fill is only the beginning. Long-term adherence is where the clinical and commercial value is realized. Self-service tools help until they don’t. The programs that hold up well build in an obvious, fast path to a real person for the moments when a patient hits friction that no workflow anticipated.
Where the Two Definitions Meet
The manufacturer’s definition of good and the patient’s definition aren’t actually in conflict. They describe the same outcome from two different points along the same journey. The same complete data picture that helps a commercial team manage a program is what allows a patient to get a proactive update instead of silence. The same reduction in handoffs that lowers a manufacturer’s operational risk is what keeps a patient from falling through the cracks between intake and adherence.
That overlap is a useful test for any DTP program, whether it’s already running or still being planned. Does a given capability serve both sides of the journey, or only one? A dashboard that tells an internal team the program is working, without changing anything the patient actually experiences, isn’t success. It’s just reporting. On the other hand, a patient-facing improvement that creates more manual work and less visibility for the manufacturer won’t hold up once the program scales.
A Simple Framework
Instead of measuring a DTP program by whether it launched on time, the industry would be better served asking three questions, each tied to a different failure point in the journey. Does the infrastructure help patients start sooner, rather than losing days to handoffs and delays? Does it help them abandon less, by removing the friction and silence that cause people to walk away mid-process? And does it help them persist longer, staying on therapy well past the first fill rather than drifting off at month two or three?
A program that holds up well against all three is one worth calling a success, regardless of how fast it launched or how media exposure came with it. A program that’s weak on even one of them probably has a gap worth closing before anyone claims victory.
The DTP conversation has largely moved past whether manufacturers should build these programs. The more useful conversation now is what “good” actually means once they have one running, from intake all the way through delivery and adherence, and that’s a definition the industry still hasn’t fully agreed on.
